ArticleNature communications2025
Provoking tumor disulfidptosis by single-atom nanozyme via regulating cellular energy supply and reducing power.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- ROS/pH-Responsive Phenylboronic Acid-Chitosan Nanoparticles Improve Silymarin-Mediated Hepatoprotection After Hepatectomy With Gut-Liver Axis-Associated Responses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Overcoming cancer stem cell resistance: advances in metabolic cell death-based nanostrategy.Science China. Life sciences · 2026Article
- Axial Coordination and Defect Engineering of Copper-Based Single-Atom Nanozymes: Driving Synergistic Disulfidptosis and Pyroptosis for Efficient Prostate Cancer Immunotherapy.Angewandte Chemie (International ed. in English) · 2026Article
- Disulfidptosis: Mechanisms, evidence boundaries, and translational opportunities.Redox biology · 2026Review
- Metabolic cell death: ferroptosis, cuproptosis, and disulfidptosis as a unified framework for targeting metabolic vulnerabilities in disease.Apoptosis : an international journal on programmed cell death · 2026Review
- An In Situ HAdvanced materials (Deerfield Beach, Fla.) · 2026Article
- Biomedical Hydrogels Based on Natural Polysaccharides: Structural Design.Gels (Basel, Switzerland) · 2026Review
- Nanoparticle-based strategies targeting disulfidptosis, anoikis, and PANoptosis for enhanced cancer therapy.Journal of nanobiotechnology · 2026Review
- Dual metabolic intervention nanoplatform co-delivering BAY-876 and L-cystine for Wilms tumor therapy via disulfidptosis-associated cytoskeletal collapse.Journal of nanobiotechnology · 2026Article
- The emerging role of disulfidptosis in metabolic synergistic death and cancer immunotherapy.Oncogenesis · 2026Review
- Electron Delocalization Induced by 3d-4f Orbital Hybridization of Co─Ce Atom Pairs Toward Enhanced Electromagnetic Wave Attenuation and Antibacterial Performance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Provoking disulfidptosis-enhanced mitophagy by manganese-based nanoplatform via regulating cellular energy supply and redox homeostasis.Materials today. Bio · 2026Article
- Metal-dependent regulated cell death: Molecular architecture and translational frontiers.iMeta · 2026Review
- Metabolic pathways and cell death modalities in diabetic complications: unraveling pyroptosis, ferroptosis, cuproptosis, and disulfidptosis.Cell death discovery · 2026Review
- [Exploring the protective effects and mechanisms of HYX1-derived exosomes on acute liver failure based on disulfidptosis signaling].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Augmenting the catalytic activity of ADzymes: strategic engineering from atomic structure design to macro-environmental interaction for enhanced biomedical efficacy.Journal of nanobiotechnology · 2026Review
- Application of Single-Atom Nanozymes in the Detection of Small Biomolecules: A Review.Molecules (Basel, Switzerland) · 2026Review
- Recent Progress and Morphological Distribution of Polydopamine-Based Biomaterials and Their Applications.Gels (Basel, Switzerland) · 2026Review
- Nanozymes in Tumor Microenvironment Modulation for Cancer Therapy.Biomaterials research · 2026Review
- Disulfidptosis: A Metabolic Cell Death Mechanism with Therapeutic Potential in Cancer.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Disulfidptosis, a recently identified form of programmed cell death, is initiated by depletion of endogenous nicotinamide adenine dinucleotide phosphate (NADPH) under glucose starvation. Tumor cells, owing to their heightened requirements of energy and nutrients, are more susceptible to disulfidptosis than normal cells. Here, we introduced an effective strategy to induce tumor disulfidptosis via interrupting cellular energy supply and reducing power by integrating a copper single-atom nanozyme (CuSAE) and glucose oxidase (GOx). GOx induces glucose starvation, impeding generation of NADPH through pentose phosphate pathway (PPP). CuSAE mimics NADPH oxidase, depleting existing NADPH, which intensifies the blockade of disulfide reduction and efficiently triggers disulfidptosis of tumor cells. Furthermore, CuSAE exhibits peroxidase- and glutathione oxidase-mimicking activities, catalyzing generation of •OH radical and depletion cellular GSH, which enhances oxidative stress and exacerbates cell damage. Disulfidptosis is confirmed as the predominant type of cell death induced by GOx/CuSAE. In vivo assays demonstrated the high antitumor potency of GOx/CuSAE in treating with female tumor-bearing mice, with minimal systemic toxicity observed. This work introduces a promising strategy for designing antitumor agents by inducing disulfidptosis. The enzyme hybrids that combine nanozymes and natural enzymes offer a feasible approach to achieve this multifaceted therapeutic goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.